We thank Vendrame and Dotta (1) for their interesting perspective regarding our recently published study investigating the role of interleukin-16 (IL-16) in the development of insulitis and type 1 diabetes in female NOD mice (2). On the basis of previous studies correlating suboptimal activation of caspase-3 with the development of autoimmunity in the clinical setting (3,4), they propose a similar condition might exist in NOD mice, resulting in defective secretion of mature IL-16. Although we have not directly examined this possibility, it must be considered that many studies have wrestled with the difficulty in detecting secreted IL-16 in several mouse strains used to examine inflammatory responses (2,5). This likely reflects the biology of mature IL-16, which is active at concentrations as low as 10−11 M, and indicates that the low levels of intrapancreatic mature IL-16 detected during the development of insulitis is not restricted only to the NOD genetic background.

However, the notion that caspase-3 activation may be suboptimal in NOD mice is suggested by several articles reporting that T cells in NOD mice exhibit an altered signaling cascade downstream of the T-cell receptor, resulting in a hyporesponsive state of activation and resistance to activation-induced cell death (68). Importantly, although it may be that a reduction in caspase-3 activation leads to diminished IL-16 secretion, this correlation has not yet been proven and the level of activated caspase-3 required for cleavage of pro–IL-16 is unknown. Thus, in support of the perspective by Vendrame and Dotta, it is uncertain how a partial deficiency in caspase-3 activation would affect levels of IL-16 secretion; but clearly, based on our results, the level of caspase-3 activation occurring in lymphocytes is sufficient for the secretion of IL-16 and recruitment of T cells needed for disease pathology. Collectively, a partial deficiency in caspase-3 activation may contribute to T-cell resistance to activation-induced cell death, which would enable autoreactive T cells to persist and may also facilitate their recruitment to islets via secretion of mature IL-16.

No potential conflicts of interest relevant to this article were reported.

1.
Vendrame
F
,
Dotta
F
.
Comment on: Meagher et al. Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism. Diabetes 2010;59:2862–2871 (Letter)
.
Diabetes
2011
;
60
:
e12
.
2.
Meagher
C
,
Beilke
J
,
Arreaza
G
, et al
.
Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism
.
Diabetes
2010
;
59
:
2862
2871
3.
Vendrame
F
,
Santangelo
C
,
Misasi
R
, et al
.
Defective lymphocyte caspase-3 expression in type 1 diabetes mellitus
.
Eur J Endocrinol
2005
;
152
:
119
125
4.
Vendrame
F
,
Segni
M
,
Grassetti
D
, et al
.
Impaired caspase-3 expression by peripheral T cells in chronic autoimmune thyroiditis and in autoimmune polyendocrine syndrome-2
.
J Clin Endocrinol Metab
2006
;
91
:
5064
5068
5.
Yoshimoto
T
,
Wang
CR
,
Yoneto
T
,
Matsuzawa
A
,
Cruikshank
WW
,
Nariuchi
H
.
Role of IL-16 in delayed-type hypersensitivity reaction
.
Blood
2000
;
95
:
2869
2874
6.
Salojin
KV
,
Zhang
J
,
Madrenas
J
,
Delovitch
TL
.
T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease
.
Immunol Today
1998
;
19
:
468
473
7.
Salojin
K
,
Zhang
J
,
Cameron
M
, et al
.
Impaired plasma membrane targeting of Grb2-murine son of sevenless (mSOS) complex and differential activation of the Fyn-T cell receptor (TCR)-zeta-Cbl pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice
.
J Exp Med
1997
;
186
:
887
897
8.
Arreaza
G
,
Salojin
K
,
Yang
W
, et al
.
Deficient activation and resistance to activation-induced apoptosis of CD8+ T cells is associated with defective peripheral tolerance in nonobese diabetic mice
.
Clin Immunol
2003
;
107
:
103
115